Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Tuesday. The firm issued a hold rating on the medical research company’s stock.

A number of other research analysts have also weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Stock Performance

Shares of Cytosorbents stock opened at $1.03 on Tuesday. The business has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $1.04. The firm has a market capitalization of $56.32 million, a P/E ratio of -2.86 and a beta of 0.58. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.59.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The business had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.14 million. During the same period in the previous year, the firm earned ($0.21) EPS. On average, equities analysts forecast that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Atomi Financial Group Inc. purchased a new position in Cytosorbents in the 3rd quarter worth about $51,000. Geode Capital Management LLC raised its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.